论文部分内容阅读
目的观察氟哌噻吨美利曲辛联合埃索美拉唑与莫沙必利治疗功能性消化不良(FD)的临床疗效。方法 96例FD患者,随机分为观察组和对照组,各48例。两组患者均给予常规剂量埃索美拉唑镁肠溶片、莫沙必利片治疗,观察组在此基础上给予氟哌噻吨美利曲辛片治疗,比较两组患者治疗前后的胃肠道症状、情绪障碍恢复情况。结果治疗8周后,观察组胃肠道症状评估总有效率(91.67%)、HAMD评估总有效率(81.40%)、HAMA评估总有效率(89.36%)高于对照组(66.67%、55.26%、54.55%)(P<0.05)。结论氟哌噻吨美利曲辛联合埃索美拉唑与莫沙必利治疗FD能明显改善患者消化道症状,有效控制患者焦虑抑郁情绪,治疗效果显著且疗效持久。
Objective To observe the clinical efficacy of flupenthixol combined with melitracen and esomeprazole and mosapride in the treatment of functional dyspepsia (FD). Methods 96 cases of FD patients were randomly divided into observation group and control group, each 48 cases. Two groups of patients were given conventional dose of esomeprazole magnesium enteric-coated tablets, mosapride tablets treatment, the observation group on the basis of flupenthixol-based melitracen tablets treatment, compared two groups of patients before and after treatment of the stomach Intestinal symptoms, mood disorders recovery. Results The total effective rate of gastrointestinal symptoms assessment (91.67%), total effective rate of HAMD assessment (81.40%) and total effective rate of HAMA assessment (89.36%) in the observation group after treatment for 8 weeks were higher in the observation group than those in the control group (66.67%, 55.26% , 54.55%) (P <0.05). Conclusions Flupenthixol and melitracen combined with esomeprazole and mosapride in treatment of FD can significantly improve gastrointestinal symptoms and control anxiety and depression in patients with significant therapeutic effect and lasting effect.